Summary
The Frederick National Laboratory for Cancer Research (operated by Leidos Biomedical Research, Inc., on behalf of the National Cancer Institute) is soliciting vendor proposals for a Service Maintenance Agreement (SMA) covering one (1) Enzymatic DNA Synthesis Platform, Model # STX-200, with a SYNTAX Gold Service Agreement including one preventive maintenance visit yearly. The period of performance will be from July 1, 2026 through June 30, 2027, and the agreement falls under NCI FFRDC master contract number 75N91019D00024. Proposals are due Friday, July 3, 2026; interested vendors must contact Nathan Lane (nate.lane@nih.gov) for the full solicitation package.